Ennature Bio Pharma lists on NSE and BSE, targets branded nutraceuticals growth
The portfolio includes thiocolchicoside, colchicine, nicotine, and vinpocetine, serving over 150 customers across 26 countries, with exports at 54% of segment revenue
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Ennature BIO Pharma (ENNATURE).
- Category: Corporate Action.
Why it matters
A routine update for Ennature BIO Pharma. Use the price and stock snapshot to gauge how the market is responding.















